Pradaxa, the first oral anticoagulant to be approved by the FDA in 50 years, comes with a well documented list of side effects, ranging from minor to life-threatening. A recent collection of studies conducted by the Cleveland Clinic has found evidence of yet another to add to that list.
Meta-analysis of these studies has shown that taking Pradaxa causes a 33% increase of acute coronary syndrom relative to that of comparable medications. Acute coronary syndrom is a blanket term for any event that causes a sudden blockage of blood flow to the heart Essentially, patients that have been been prescribed and are taking Pradaxa are up to 33% more likely to suffer a heart attack or other serious heart conditions than those who are taking other anticoagulants, like Coumadin.
Despite Pradaxa’s dangerous side effects that also include a reduction in kidney function (especially in older patients) and risk of severe and uncontrolled bleeding, it’s manufacturer, Boehringer Ingelheim, has concluded that the benefits it provides outweigh any potential risk. Pradaxa has been proven to reduce the risk of stroke in patients suffering from atrial fibrillation.
However, with occurrences of fatal side effects mounting, currently over 260 such instances have been reported world wide, the FDA has decided to re-evaluate Pradaxa, although no recall has been issued at this point. Patients who have been taking Pradaxa and have experienced any of these side effects should consult an experienced Pradaxa attorney to answer any questions you may have.